Share

Louise E. Wilkins-Haug

M.D., Ph.D.

Division Director, Maternal Fetal Medicine and Reproductive Genetics

Brigham and Women’s Hospital

Clinical Lead, Maternal Fetal Care Center, Boston Children’s Hospital

Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Dr. Louise Wilkins-Haug is the Division Director of Maternal Fetal Medicine and Reproductive Genetics at the Brigham and Women’s Hospital. She is board-certified in Medical Genetics, Obstetrics and Gynecology and Maternal Fetal Medicine.  Dr. Wilkins-Haug received her bachelor's degree from James Madison University in Biology. She completed her PhD in Human Genetics at Medical College of Virginia.  She received her MD degree in Medicine at Stanford University School of Medicine.  She has over two decades of experience leading a prenatal Down syndrome screening program and currently oversees the genetic counseling, perinatal consultation, fetal treatment and diagnostic testing at BWH. She is an active clinical provider in the Maternal Fetal Medicine practice and provides continuity care for women with high risk pregnancies. This high-risk office has a national and international referral base and provides care and delivery for >2000 women a year. From this experience, she has witnessed the challenges faced by obstetric providers with the evaluation and application of genetic testing for stillbirth, leading to our institution’s implementation of a standard protocol for clinical evaluation of stillbirth and quarterly reviews of all stillbirths at BWH.

Dr. Wilkins-Haug has been the lead fetal interventionist for a 20-year collaborative program with Boston Children's Hospital to alter the natural in utero history of aortic stenosis evolving to hypoplastic left heart syndrome.  Our program established the safety and efficacy of fetal aortic valve dilation, and continues to assess predictors of success, examines cardiac, medical and neurologic outcomes and participates in the training of individuals who have successfully established similar programs at institutions worldwide.

Louise E. Wilkins-Haug

M.D., Ph.D.

Division Director, Maternal Fetal Medicine and Reproductive Genetics

Brigham and Women’s Hospital

Clinical Lead, Maternal Fetal Care Center, Boston Children’s Hospital

Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Dr. Louise Wilkins-Haug is the Division Director of Maternal Fetal Medicine and Reproductive Genetics at the Brigham and Women’s Hospital. She is board-certified in Medical Genetics, Obstetrics and Gynecology and Maternal Fetal Medicine.  Dr. Wilkins-Haug received her bachelor's degree from James Madison University in Biology. She completed her PhD in Human Genetics at Medical College of Virginia.  She received her MD degree in Medicine at Stanford University School of Medicine.  She has over two decades of experience leading a prenatal Down syndrome screening program and currently oversees the genetic counseling, perinatal consultation, fetal treatment and diagnostic testing at BWH. She is an active clinical provider in the Maternal Fetal Medicine practice and provides continuity care for women with high risk pregnancies. This high-risk office has a national and international referral base and provides care and delivery for >2000 women a year. From this experience, she has witnessed the challenges faced by obstetric providers with the evaluation and application of genetic testing for stillbirth, leading to our institution’s implementation of a standard protocol for clinical evaluation of stillbirth and quarterly reviews of all stillbirths at BWH.

Dr. Wilkins-Haug has been the lead fetal interventionist for a 20-year collaborative program with Boston Children's Hospital to alter the natural in utero history of aortic stenosis evolving to hypoplastic left heart syndrome.  Our program established the safety and efficacy of fetal aortic valve dilation, and continues to assess predictors of success, examines cardiac, medical and neurologic outcomes and participates in the training of individuals who have successfully established similar programs at institutions worldwide.

Recent Publications

Prenatal diagnosis of sex chromosome aneuploidy-What do we tell the prospective parents?

Published On 2022 Nov 01

Journal article

Sex chromosome aneuploidy (SCA) can be detected on prenatal diagnostic testing and cell free DNA screening (cfDNA). High risk cfDNA results should be confirmed with diagnostic testing. This summary article serves as an update for prenatal providers and assimilates data from neurodevelopmental, epidemiologic, and registry studies on the most common SCA. This information can be helpful for counseling after prenatal diagnosis of sex chromosome aneuploidy. Incidence estimates may be influenced by...